Navigation Links
BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
Date:4/8/2008

NOVATO, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, April 29, at 5:00 p.m. ET (23:00 CET) to discuss first quarter 2008 financial results.

U.S. / Canada Dial-in Number: 866.713.8310

International Dial-in Number: 617.597.5308

Participant Code: 30774883

Replay Dial-in Number: 888.286.8010

Replay International Dial-in Number: 617.801.6888

Replay Code: 22123696

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
2. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
3. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
4. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
5. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
6. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
7. BioMarin to Present at the BioCentury NewsMakers Conference
8. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
9. Boston Scientific to Webcast Conference Call Discussing First Quarter Financial Results
10. More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheims Flomax as First-Line Therapy
11. Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015  Novartis is highlighting data ... CTL019, an investigational chimeric antigen receptor (CAR) T ... treatment of specific types of hard-to-treat non-Hodgkin lymphoma. ... University of Pennsylvania,s Perelman School of Medicine (Penn) ... large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) ...
(Date:6/1/2015)... TRIANGLE PARK, N.C. , June 1, 2015 ... announced the presentation of positive interim results from ... SIOPEL6: A multi-centre open label randomised phase III ... in reducing ototoxicity in patients receiving cisplatin (Cis) ... was presented at the American Society of Clinical ...
(Date:6/1/2015)... Resverlogix Corp. (TSX: RVX) (the "Company") today announced that  ... Congress in London, England in ... BET-Inhibitor, on Key Renal Parameters in Subjects with a ... Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ... Kalantar-Zadeh , Professor and Chief, Division of Nephrology and Hypertension at University ...
(Date:6/1/2015)... N.Y. , June 1, 2015 /PRNewswire/ ... ) announced today that it has signed ... LLC to co-market their structure-based drug discovery ... As part of the three-year agreement, AMRI ... structure-determination expertise and capabilities. HarkerBIO,s customers will ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 2AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 3
... Amicus Therapeutics (Nasdaq: FOLD ) will announce ... of markets on Thursday, May 7, 2009. The results ... and webcast that afternoon at 5 p.m. EDT. Interested ... 5 p.m. EDT by dialing 877-874-1565 (U.S./Canada) or 719-325-4830 ...
... Microfluidics and Imaging -- Net Loss Narrowed by $0.07 per ... (Nasdaq: CALP ) today reported its first quarter ... million compared to $29.3 million in the first quarter of ... 2008 included $2.9 million of revenue related to product lines ...
... of its fifth Best Practices Awards program. Grand Prize winners ... Broad Institute of MIT and Harvard, Genedata, Genentech, GlaxoSmithKline, Merck & ... Research. , ... Needham, Mass (PRWEB) April 29, 2009 ...
Cached Biology Technology:Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date 2Caliper Life Sciences Reports First Quarter 2009 Results 2Caliper Life Sciences Reports First Quarter 2009 Results 3Caliper Life Sciences Reports First Quarter 2009 Results 4Caliper Life Sciences Reports First Quarter 2009 Results 5Caliper Life Sciences Reports First Quarter 2009 Results 6Caliper Life Sciences Reports First Quarter 2009 Results 7Caliper Life Sciences Reports First Quarter 2009 Results 8Caliper Life Sciences Reports First Quarter 2009 Results 9Caliper Life Sciences Reports First Quarter 2009 Results 10Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 2Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 3Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 4Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 5Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 6
(Date:5/11/2015)... May 11, 2015  Through a well-rounded UAS delegation representing ... had a strong showing at AUVSI,s Unmanned 2015 conference last ... Ohio,s UAS industry met with over ... all points along the UAS ecosystem. "Our ... Vice President for Aerospace Rich Knoll . "If you ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... Meeting on Acoustics -- a major international acoustics conference ... Coral Beach Hotel in Cancun, Mexico. Reporters are invited ... http://www.acoustics.org/press The press room contains news releases ... more than a thousand presentations at the meeting, which ...
... With so few Americans consuming the recommended amounts of fruit ... fruit servings and the important nutrients they provide ... of 100 percent juice supplies one serving (1/2 cup) of ... New research presented today at the American Dietetic Association (ADA) ...
... UNC scientists describes how cells infected by the Epstein-Barr ... changing their cellular "cargo" of proteins and RNA. This ... of recipient cells from benign to cancer-producing. In ... potentially manipulate other cells throughout the body. The findings ...
Cached Biology News:Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 2Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 3Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 4Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 5Drinking 100 percent fruit juice is linked to higher intake of essential nutrients 2UNC scientists identify cellular communicators for cancer virus 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
... 2/3D Waver Shaker combines shaking and rocking for ... 330 x 330 mm stainless steel or acrylic ... and cold room operation. The platform angle is ... a vigorous with action and rotation speed of ...
... kit for 25 chips provides the chips ... analysis (at picogram levels) with the Experion ... RNA HighSens microfluidic chips, 2 x 1,250 ... RNA HighSens stain, 20 microliters RNA ladder, ...
Biology Products: